All In Biotech

Drug Trial Radar · NCT00838357

A Multi-centre, Open Label, Single-arm Study Intended to Further Investigate the Safety and Efficacy of Plerixafor as a Front-line Mobilisation Agent in Combination With G-CSF in Patients With Lymphoma or MM (Multiple Myeloma).

Plerixafor and G-CSF for the Mobilisation of Peripheral Blood Stem Cells for Autologous Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM) - Safety Study in a General Autologous Transplant Population

Last checked: Nov 20, 2026Latest source record: Mar 24, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

118

Actual

Start

Sep 2008

Primary completion

Nov 2010

Study completion Nov 2010

Sponsor

Lead sponsor
Genzyme, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Feb 6, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a research study intended to further investigate the safety and efficacy of plerixafor in patients with NHL, HD, or MM. Patients who have previously failed stem cell mobilisation attempts or who have previously received more than one autologous or any allogeneic stem cell transplant are not eligible.

Conditions

  • Lymphoma (Non-Hodgkin's Lymphoma)
  • Hodgkin's Disease or Multiple Myeloma
  • Front Line Mobilization
  • Transplantation

Interventions

  • Generic = PlerixaforDrug

    240µg/kg administered as an SC injection 10 to 11 hours prior to initiation of apheresis. Daily administration for 1 up to 5 consecutive days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To confirm the safety profile of plerixafor to mobilise stem cells when used in patients with lymphoma or MM who are eligible to undergo treatment with an autologous haematopoietic stem cell transplantTime frame: 24 months

Locations

26 sites in 7 countries. Site status is shown where the registry gives one.

  • Hôpital du Haut Lévêque

    Bordeaux, France

  • Hôpital Lyon Sud

    Lyon, France

  • Institut Paoli Calmettes

    Marseille, France

  • CHU Hotel-Dieu Université de Nantes

    Nantes, France

  • Hôpital Saint-Louis

    Paris, France

  • Institut Gustave Roussy

    Villejuif, France

  • Charité - Campus Benjamin Franklin

    Berlin, Germany

  • Klinikum der Universität zu Köln

    Cologne, Germany

  • Universitätsklinikum Carl Gustav Carus

    Dresden, Germany

  • Universitätsklinikum Heidelberg

    Heidelberg, Germany

  • Klinikum Nürnberg Nord

    Nuremberg, Germany

  • Universitätsklinik Würzburg

    Würzburg, Germany

  • L. & A. Seragnoli, University of Bologna

    Bologna, Italy

  • Ospedale Ferrarotto

    Catania, Italy

  • Azienda Ospedaliera S. Martino

    Genova, Italy

  • VU Medisch Centrum

    Amsterdam, Netherlands

  • Hospital Santa Creu y Sant Pau

    Barcelona, Spain

  • Hospital Carlos-Haya

    Málaga, Spain

  • Hospital Universitario de Salamanca

    Salamanca, Spain

  • Hospital la Fe

    Valencia, Spain

  • Karolinska Universitetssjukhuset Huddinge

    Stockholm, Sweden

  • Akademiska Sjukhuset

    Uppsala, Sweden

  • Gartnavel Hospital

    Glasgow, United Kingdom

  • St James's University Hospital

    Leeds, United Kingdom

  • King's college Hospital

    London, United Kingdom

  • Nottingham University NHS Trust

    Nottingham, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.